Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Apr 30:5:9905.
doi: 10.1038/srep09905.

Meta-Analysis of the Relationship between XRCC1-Arg399Gln and Arg280His Polymorphisms and the Risk of Prostate Cancer

Jie Yan  1 , Xiantao Wang  2 , Hui Tao  1 , Zengfu Deng  1 , Wang Yang  1 , Faquan Lin  1
Affiliations
Meta-Analysis

Meta-Analysis of the Relationship between XRCC1-Arg399Gln and Arg280His Polymorphisms and the Risk of Prostate Cancer

Jie Yan et al. Sci Rep. .

Erratum in

Abstract

Prostate cancer is one of the most common noncutaneous malignancies in Western countries. Because there has been a debate regarding the relationship between the XRCC1-Arg399Gln and Arg280His polymorphisms and prostate cancer risk, we therefore performed this meta-analysis. The electronic databases PubMed, EMBASE, and Medline were searched prior to October 1, 2014. An odds ratio and 95% confidence interval were used to calculate association. Heterogeneity was tested by both a chi-square test and I statistic. Funnel plots and Egger's test were used to assess publication bias. All statistical analyses were performed using STATA 12.0 software. A significant association between the XRCC1-Arg399Gln polymorphism and prostate cancer risk was found under a homozygote model and a recessive model. A significant association between XRCC1-Arg280His and prostate cancer risk was found under a heterozygote model and a dominant model [corrected]. Overall, the results of this meta-analysis show that the XRCC1-Arg399Gln polymorphism may be associated with an increased risk for prostate cancer under the homozygote model and the recessive model. And XRCC1-Arg280His polymorphism is likely to be related with prostate cancer risk under the heterozygote model and the dominant model. Additional larger well-designed studies are needed to validate our results.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of the study selection.
Figure 2
Figure 2. (a) Forest plot of XRCC1-Arg399Gln and prostate cancer under the homozygote model (GG vs. AA).
(b) Forest plot of XRCC1-Arg399Glnand prostate cancer under the recessive model (GG vs. AA + AG). (c) Forest plot of XRCC1-Arg280His and prostate cancer under the heterozygote model (AH vs. AA). (d) Forest plot of XRCC1-Arg280His and prostate cancer under the dominant model (HH + HA vs. AA).
Figure 3
Figure 3. (a) Cumulative meta-analysis of the XRCC1-Arg399Gln polymorphism and prostate cancer.
(b) Cumulative meta-analysis of theXRCC1-Arg280His polymorphism and prostate cancer risk.
Figure 4
Figure 4. Sensitivity analysis of the XRCC1-Arg399Gln polymorphism and prostate cancer risk.
Figure 5
Figure 5. Funnel plot for publication bias in the meta-analysis of the XRCC1-Arg399Gln polymorphism and prostate cancer risk.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dianat S. S. et al. Gene polymorphisms and prostate cancer: the evidence. BJU international 104, 1560–1572 (2009). - PubMed
    1. Hamano T., Matsui H., Ohtake N., Nakata S. & Suzuki K. Polymorphisms of DNA repair genes, XRCC1 and XRCC3, and susceptibility to familial prostate cancer in a Japanese population. Asia-Pacific Journal of Clinical Oncology 4, 21–26 (2008).
    1. Ritchey J. D. et al. Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol. Biomarkers Prev. 14, 1703–1709 (2005). - PubMed
    1. Zhang J., Dhakal I. B., Greene G., Lang N. P. & Kadlubar F. F. Polymorphisms in hOGG1 and XRCC1 and risk of prostate cancer: effects modified by plasma antioxidants. Urology 75, 779–785 (2010). - PMC - PubMed
    1. Goode E. L., Ulrich C. M. & Potter J. D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1513–1530 (2002). - PubMed

Publication types

Substances